Document Detail


Current pharmacologic management of pediatric heart failure in congenital heart disease.
MedLine Citation:
PMID:  21314633     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pharmacologic therapy represents the mainstay of treatment for heart failure in children. However, medical therapy for this population is not widely standardized. This is mainly due to the heterogeneity of potential etiologies, the specific challenge of patients with univentricular physiology and the lack of evidence-based prospective randomized clinical trials in pediatric patients. In fact, most current strategies are based largely on extrapolated data from adult studies. Although the classic drugs for heart failure, i.e. diuretics, angiotensin-converting enzyme inhibitors, ß -blockers and cardiac glycosides, still play a major role in the treatment of pediatric heart failure, newer alternative therapies such as levosimendan and nesiritide are increasingly utilized with promising early results. A systematic literature search of PubMed and MEDLINE databases using relevant terms was performed. All clinical trials and relevant manuscripts about the current pharmacologic treatment of heart failure in the pediatric population were reviewed. New drugs such as levosimendan and nesiritide and the treatment of single-ventricle patients were also included.
Authors:
Victor Bautista-Hernandez; Antonio Sanchez-Andres; Francisco Portela; Francis Fynn-Thompson
Related Documents :
3791333 - Importance of retrograde coronary flow in the prediction of experimental myocardial inf...
10509993 - Importance of acquired systemic-to-pulmonary collaterals in the fontan operation.
24379183 - Atrial natriuretic peptide affects cardiac remodeling, function, heart failure, and sur...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  9     ISSN:  1875-6212     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-11     Completed Date:  2011-12-19     Revised Date:  2012-03-26    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  619-28     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Surgery, Children´s Hospital Boston-Harvard Medical School, Boston, MA, USA. victor.bautista.hernandez@sergas.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  therapeutic use
Child
Diuretics / administration & dosage,  therapeutic use
Heart Defects, Congenital / complications*,  physiopathology
Heart Failure / diagnosis,  drug therapy*,  epidemiology,  etiology
Hemodynamics / drug effects
Humans
Hydrazones / administration & dosage,  therapeutic use
Incidence
Natriuretic Peptide, Brain / administration & dosage,  therapeutic use
Pyridazines / administration & dosage,  therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Diuretics; 0/Hydrazones; 0/Pyridazines; 114471-18-0/Natriuretic Peptide, Brain; 131741-08-7/simendan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment and Clinical Relevance of Non-fasting and Postprandial Triglycerides: An Expert Panel Sta...
Next Document:  What Restricts the Clinical Use of Nicotinic Acid?